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Neoplastic cells accumulate magnesium, an event which provides selective advantages and is 
frequently associated with TRPM7overexpression. Little is known about magnesium homeostasis 
in drug-resistant cancer cells. Therefore, we used the colon cancer LoVo cell model and compared 
doxorubicin-resistant to sensitive cells. In resistant cells the concentration of total magnesium is 
higher while its influx capacity is lower than in sensitive cells. Accordingly, resistant cells express 
lower amounts of the TRPM6 and 7, both involved in magnesium transport. While decreased TRPM6 
levels are due to transcriptional regulation, post-transcriptional events are involved in reducing the 
amounts of TRPM7. Indeed, the calpain inhibitor calpeptin markedly increases the levels of TRPM7 
in resistant cells. In doxorubicin-sensitive cells, silencing TRPM7 shifts the phenotype to one more 
similar to resistant cells, since in these cells silencing TRPM7 significantly decreases the influx of 
magnesium, increases its intracellular concentration and increases resistance to doxorubicin. On the 
other hand, calpain inhibition upregulates TRPM7, decreases intracellular magnesium and enhances 
the sensitivity to doxorubicin of resistant LoVo cells. We conclude that in LoVo cells drug resistance 
is associated with alteration of magnesium homeostasis through modulation of TRPM7. Our data 
suggest that TRPM7 expression may be an additional undisclosed player in chemoresistance.
Cancer exacts a very high toll as one of the leading causes of death all over the world. A complex hurdle 
in cancer treatment is the development of resistance to anticancer drugs, which is attributable to the 
expression of specific transporters that protect the neoplastic cells from harmful molecules1. However, it 
is increasingly evident that many other corollary mechanisms contribute to render cancer cells resistant 
to anti-neoplastic drugs. Among others, metals, which are essential in most cellular process, seem to be 
implicated. In particular, intracellular calcium (Ca) concentration is higher and its distribution within 
the cell is different in sensitive vs resistant cells2. Relatively little is known about magnesium (Mg), which 
is essential for life as a cofactor for ATP and hundreds enzymes, and also plays a part in intracellular 
signaling3.
Intracellular Mg is higher in cisplatin resistant than in sensitive ovarian carcinoma cells4. In drug 
resistant gastric cancer cells, the mitochondrial Mg transporter Mrs2 is upregulated and this inhibits 
doxorubicin (DXR)-induced apoptosis5.
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In general, intracellular Mg homeostasis is maintained by the ubiquitously expressed ion channel tran-
sient receptor potential melastatin (TRPM)7, which shows the functional duality of being an ion channel 
and a kinase6. TRPM7 shares a very high homology with TRPM6, which is particularly abundant in the 
epithelium of the colon and the kidney and mainly involved in regulating body Mg balance7,8. TRPM6 
and 7 are not functionally redundant8,9. Accordingly, they do not complement for each other’s deficiency 
in TRPM7-/- B lymphocytes10, in TRPM6-/- and TRPM7-/- mice11,12. It is noteworthy that TRPM6 and 
7 kinases have different substrate specificity. In particular, while both TRPM6 and 7 autophosphorylate 
their threonine residues, TRPM6 phosphorylates TRPM7, but not the opposite9. TRPM7 stands as the 
most intriguing of the two chanzymes as it is associated with a wide variety of biological functions13. It is 
noteworthy that the kinase activity is not essential for channel gating and in vitro annexin A1 and myosin 
IIA heavy chain have been shown to be substrates for the TRPM7 kinase8. In addition, a recent study 
has demonstrated that TRPM7’s kinase domain is proteolitically released from the channel and kinase 
cleaved fragments translocate to the nucleus and bind multiple components of chromatin-remodeling 
complexes, thus modulating the phosphorylation of specific histones14.
TRPM7 over-expression has been described in various human cancer cells including pancreatic, 
breast, ovarian, and head and neck carcinoma cells15–18, but no data are available about the expression of 
TRPM7 in drug sensitive or resistant tumor cells.
In turn, little is known about TRPM6 and cancer. A Boolean-based system biology approach has 
predicted TRPM6 as a potential drug candidate to prevent tumor growth19.
We performed our studies on colon carcinoma LoVo cells which are DXR-sensitive or resistant 
(LoVo-S and LoVo-R, respectively). Differences in energy metabolisms between LoVo-S and LoVo-R 
have been described20. In particular, the enhancement of energy-yielding pathways in LoVo-R correlates 
with higher levels of ATP than in LoVo-S20. Accordingly, a proteomic analysis has shown the differen-
tial expression of proteins involved in energy and detoxification pathways, cell survival, and chaperone 
function21. Recently, using a novel quantitative chemical imaging approach, we have shown the different 
Mg compartmentalization in LoVo-R compared to LoVo-S. In LoVo-R Mg was particularly abundant in 
the nucleus, while in LoVo-S Mg was mainly in the perinuclear region22.
We here measure total and free intracellular Mg, Mg fluxes, and the expression of TRPM6 and 7 in 
LoVo-R and -S. We also investigate the role of TRPM7 in modulating the sensitivity of LoVo cells to DXR 
and demonstrate that in this model of colon carcinoma cells drug resistance is associated with alteration 
of Mg homeostasis through modulation of TRPM7.
Results
Mg homeostasis in LoVo cells. Initially we measured total and free Mg in LoVo cells. Total Mg was 
higher in LoVo-R than in LoVo-S (Fig. 1a), while free Mg was not significantly altered (Fig. 1b).
We then investigated Mg influx capacity in Mag-Fluo-4-loaded LoVo-S and LoVo-R by live confo-
cal imaging23. As shown in Fig.  1c, LoVo-S intracellular fluorescence displayed a rapid and consistent 
increase reaching a plateau within 2 minutes. At plateau LoVo-R showed an intracellular fluorescence 
increase which accounts for 50% of the increase observed in LoVo-S (Fig. 1d). Mg efflux did not display 
any significant difference in LoVo-S and R in our experimental conditions (Supplementary Fig. S1).
To get insights into these puzzling results, we evaluated the expression of TRPM6 and 7, the first 
molecularly defined components of the mammalian Mg transport machinery. LoVo-R expressed signif-
icantly lower amounts of TRPM6 RNA than LoVo-S, while the levels of TRPM7 RNA were comparable 
in the two cell types as detected by real time-PCR (Fig. 2a). By western blot, however, the total amounts 
of both TRPM6 and 7 were markedly reduced in LoVo-R in respect to LoVo-S (Fig. 2b-Supplementary 
Fig. S2).
The contribution of calpains to Mg homeostasis in LoVo cells. We investigated whether the 
reduced amounts of TRPM7 in LoVo-R could be due to degradation by intracellular proteases. Initially, 
we performed some studies in vitro on LoVo-S cell lysates to evaluate whether different cations, which are 
cofactors for several proteases, influenced the stability of TRPM7. Cell lysates were incubated in the pres-
ence of 3 mM of CaCl2, MgCl2 or ZnCl2 for 30 min at room temperature. While the addition of ZnCl2 and 
MgCl2 had no effects on TRPM7 levels, the addition of CaCl2 caused a marked reduction of the amounts 
of the protein. The Ca chelator EDTA prevented the degradation of TRPM7 (Fig. 3a-Supplementary Fig. 
S3A). These data demonstrate that Ca triggers TRPM7 degradation. We then evaluated TRPM7 levels 
in LoVo-R cultured in the presence of the proteasome inhibitor MG132 (5 μ M), the calpain inhibitor 
calpeptin (2.5 and 5 μ g/ml), chloroquine (100 μ M) and bafilomycin (100 nM), which inhibit lysosomal 
activity. We found that, while bafilomycin, chloroquine and MG132 had little effect (less than 1.3 fold 
induction), 5 μ g/ml calpeptin markedly increased TRPM7 in LoVo-R to levels comparable to those 
detected in LoVo-S (Fig. 3b- Supplementary Fig. S3B). To this purpose, it is noteworthy that calpeptin 
did not affect cell viability at the concentrations used as detected by MTT assay (Supplementary Fig. 
S3C).
The increment of TRPM7 by calpeptin was associated with a significant dose-dependent reduction of 
total intracellular Mg (Fig. 3c), thus indicating that in these cells an inverse correlation exists between 
total intracellular Mg and the levels of TRPM7.
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Figure 1. Mg levels and influx in LoVo-S and LoVo-R. (a) Total Mg was measured using the 
fluorescent chemosensor DCHQ5 as described. (b) Free Mg was measured using Mag-Fura-2-AM as 
described. (c) Time course of magnesium influx in Mag–Fluo-4-loaded cells was performed by live confocal 
imaging and single-cell fluorescence was evaluated by image analysis. The mean fluorescence (Δ F/F) of 
10 cells ± standard deviation from a representative experiment is reported. (d) Fluorescence increment in 
LoVo-S and LoVo-R cells was measured at t = 150 s and normalized to LoVo-S cell values.
Figure 2. TRPM6 and 7 expression in LoVo-S and LoVo-R. (a) Real-Time PCR was performed on RNA 
extracted from LoVo cells using primers designed on TRPM6 and 7 sequence. (b) LoVo cells were lysed and 
utilized for Western blot using antibodies against TRPM6 and 7. Actin was used as a control of loading. A 
representative blot is shown.
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Because Ca i) is known to activate calpains24 and ii) is higher in resistant than in sensitive cells2, 
we measured intracellular free Ca and found that it is significantly higher in LoVo-R than in LoVo-S 
(Fig. 3d).
The contribution of TRPM7 to Mg homeostasis in LoVo cells. We focused our studies on the role 
of TRPM7 in regulating Mg homeostasis in our experimental model by transiently transfecting LoVo-S 
with specific siRNAs or with a non-silencing siRNA sequence as a control. The silencing of TRPM7 was 
confirmed by western blot. A significant reduction in the total amounts of the channel was observed 48 
and 72 hours after transfection (Fig. 4a- Supplementary Fig. S4). It is noteworthy that silencing TRPM7 
does not impact on the levels of TRPM6 (Fig. 4a- Supplementary Fig. S4).
We then measured Mg influx in Mag-Fluo-4-loaded LoVo-S after silencing TRPM7 and found it sig-
nificantly reduced, thus confirming that TRPM7 involvement in modulating Mg transport is fundamen-
tal in LoVo cells (Fig. 4b). However, total intracellular Mg was significantly increased in cells silencing 
TRPM7 (Fig.  4c). These results show that LoVo-S silencing TRPM7 mimic LoVo-R since low levels of 
TRPM7 are associated with an increased intracellular concentration of total Mg.
The contribution of TRPM7 to DXR resistance in LoVo cells. To find a causal relationship 
between TRPM6/TRPM7 function and drug resistance in LoVo cells, LoVo-S were silenced for TRPM6 
and TRPM7 or treated with TRPM7 channel blocker 2-aminoethoxydiphenyl borate (2-APB, 50µM). 
15 hours later, the cells were challenged with DXR (1 μ g/ml) and their viability was assessed by MTT 
assay. As shown in Fig. 5a, after DXR treatment about 42% of LoVo-S remained viable vs. 89% of LoVo-R, 
as expected. While silencing TRPM6 (Supplementary Fig. S5A) reduced cell survival, silencing TRPM7 
increased cell survival (about 63% of viable LoVo-S after DXR treatment). 2-APB markedly increased 
cell survival without reaching the statistical significance. However, when we exposed LoVo-S to 2-APB 
for 15 h and then measured DXR retention, we found that LoVo-S behave like LoVo-R and retain lower 
amounts of DXR (Fig. 5b and Supplementary S5B).
We also treated LoVo-R with calpeptin and then challenged them with DXR. Calpeptin, which upreg-
ulates TRPM7 and decreases intracellular Mg, renders the cells more sensitive to the toxic effect of DXR 
(Fig. 5a).
Overall, these results suggest that interfering either with the expression or the activity of TRPM7 
affects the sensitivity of LoVo cells to DXR.
Figure 3. Ca-dependent TRPM7 degradation in vitro and in vivo, and effect on total Mg level. 
(a) LoVo-S cell extracts were incubated in a buffer containing 3 mM of CaCl2, MgCl2 or ZnCl2 for 30 min 
at room temperature. One sample was incubated with 3 mM of CaCl2 in the presence of EDTA (10 mM). 
The samples were immunoblotted with an antibody against TRPM7. (b) LoVo-R were treated with MG132 
(5 μ M), bafilomycin (100 nM), chloroquine (100 μ M) or calpeptin (2.5 or 5.0 μ g/ml) for 16 h at 37 °C. 
Western blot was performed on cell lysates with anti-TRPM7 antibodies. Actin was used to show that equal 
amounts of proteins were loaded per lane. (c) After 16 h exposure to calpeptin (2.5 or 5.0 μ g/ml), total Mg 
was measured using the fluorescent chemosensor DCHQ5 as described. Data are shown as the change in 
Δ % of intracellular total Mg content in calpeptin treated LoVo-R cells referred to untreated LoVo-R cells. 
(d) Intracellular free Ca was measured using Fura-2-AM as described.
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Discussion
High intracellular Mg selectively advantages neoplastic cells, since it reprograms metabolism, activates 
telomerase and inactivates p53 through the inhibition of the nuclear Ser/Thr phosphatase PPM1D25. A 
link between low extracellular magnesium and the risk of colon cancer has been shown25. Moreover, a 
single nucleotide polymorphism that substitutes TRPM7 threonine 1482 (T1482) to isoleucine (T1482I) 
increases the risk of development of colon cancer25,26. Interestingly, TRPM7 T1482 is a potential site of 
phosphorylation by TRPM6. It is therefore possible to hypothesize a different regulation of the TRPM7 
T1482I channel by TRPM6, which might be involved in promoting the acquisition of a neoplastic phe-
notype. On these bases, TRPM6 and 7 are emerging as puzzling, potential players in colon cancer.
We here investigate the cellular handling of Mg in human colon carcinoma cells sensitive or resistant 
to DXR and its contribution to drug resistance.
By a novel quantitative chemical imaging approach that combines synchrotron radiation microscopy 
with atomic force microscopy, we have recently shown a higher concentration of total intracellular Mg 
in LoVo-R than LoVo-S, and a different pattern in the spatial distribution of molar Mg concentration22. 
In particular, LoVo-R displayed the highest values of molar Mg concentration within the nucleus, while 
LoVo-S showed the highest values in the peri-nuclear region. This feature was not evident for all the 
other elements evaluated in this study, which suggests that Mg compartmentalization could be a sig-
nificant trait of the drug resistant cells22. We here report quantitative data showing the increase of total 
intracellular Mg in LoVo-R vs LoVo-S, thus providing additional evidence on the different content of 
Figure 4. TRPM7 silencing, Mg influx and concentration in LoVo-S. (a) LoVo-S were transfected with a 
siRNA against TRPM7. Cell extracts obtained 48 and 72 hours after transfection were run on two separate 
gels under the same experimental conditions. Western blot was performed using antibodies against TRPM6 
and 7. Actin was used as a control of loading. (b) Time course of Mg influx in control (CTR) and TRPM7-
silenced LoVo-S. Cells were transfected with a TRPM7-specific siRNA and analysed by live confocal imaging 
after 72 h (upper panel). Fluorescence increment in control and TRPM7-silenced LoVo-S was measured at 
t = 150s and normalized to control values (lower panel). (c) Total intracellular Mg was measured in LoVo-S 
after silencing TRPM7 using the fluorescent chemosensor DCHQ5.
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total intracellular Mg in the two cell types. It is noteworthy that total Mg content was higher also in 
cisplatin-resistant human ovarian carcinoma cells when compared to parental sensitive cells and this 
seems to be responsible for the impairment of apoptosis in resistant cells4. In LoVo-S and -R, we found 
no significant differences in free Mg. This result is in agreement with previous studies showing that intra-
cellular cytosolic free Mg is relatively unchanged during cellular massive translocation of total Mg27,28. 
Thanks to those pioneering studies the notion that free intracellular Mg and total intracellular Mg behave 
differently and are differently regulated is a consolidated concept and finds here additional support.
Significant increases in free Mg are observed only in dramatic metabolic perturbations, i.e. after 
ischemia, while after physiologic signaling cytosolic free Mg remains constant. Not only cytosolic free 
Mg was the same in LoVo-R and -S, but also we could not detect significant differences in Mg efflux 
between LoVo-R and -S.
We hypothesize that the higher concentration of total intracellular Mg in spite of its reduced influx 
might be explained by the different metabolic profile of LoVo-R vs LoVo-S that accounts for different 
concentrations of buffering components20.
It is noteworthy that the levels of TRPM7 are inversely related to the amounts of total intracellular 
Mg. Briefly, LoVo-R, which have higher intracellular Mg than LoVo-S, downregulate TRPM7. Conversely, 
LoVo-S silencing TRPM7 have more intracellular Mg than controls. Interestingly, the same results were 
obtained in human endothelial cells derived from the umbilical vein. Indeed, high extracellular Mg, 
which increases total intracellular Mg29, downregulates TRPM7 through the activation of calpains, 
intracellular Ca-dependent cysteine proteases which are involved in a large number of physiological 
and pathological events24. Accordingly, TRPM7 was markedly reduced in resistant cells because of the 
activation of calpains. Since calpains are Ca-dependent, it should be recalled that free Ca is higher in 
LoVo-R than in LoVo-S, as previously demonstrated in different cell types resistant to drugs2. In Lovo-R 
calpeptin, a specific calpain inhibitor which prevents the binding and subsequent proteolysis of calpain 
Figure 5. Modulation of TRPM7 expression and/or activity affects sensitivity of LoVo cells to DXR. 
(a) Where indicated, LoVo-S were either silenced for TRPM6 or TRPM7 as detailed in the Materials and 
Methods section, or pretreated with the TRPM7 channel blocker 2-APB (50 μ M), while LoVo-R were 
exposed to calpeptin (5 μ g/ml). After 16 h the cells were challenged with DXR (1 μ g/ml) for 48 h. Cell 
viability after DXR treatment was assessed by MTT assay. Percentage cell viability was calculated from the 
absorbance measured in DXR-treated vs. untreated cells for each condition. Data are mean ± SEM (n = 4). 
Statistical significance was assessed by Student’s t test referred to control LoVo-S (CTR, black bar) or control 
LoVo-R (CTR, white bar). (b) Cells were incubated with DXR for 2 h and were either immediately fixed 
(loading control) or allowed further 30 min in medium without DXR before fixing (efflux). Percentage DXR 
retention was quantified as the mean nuclear fluorescence measured in efflux conditions vs. loading control. 
Data are mean ± SEM (n = 80). Where indicated, LoVo-S cells were pretreated with 2-APB (50µM, 15 h). 
Statistical significance was assessed by Student’s t test referred to control LoVo-S (CTR).
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substrates30, augments TRPM7 to levels comparable to those found in LoVo-S and, in agreement with the 
results discussed above, decrease the total amount of intracellular Mg. Therefore calpains are emerging as 
important modulators of Mg homeostasis. Interestingly, TRPM7 is a potent regulator of m-calpain and 
co-localizes with the enzyme at peripheral adhesion complexes in HEK293 cells31,32. On these bases, we 
propose the existence of an interplay between calpains and TRPM7 where TRPM7 is both a regulator 
and a target of these enzymes.
Also TRPM6 is downregulated in LoVo-R. The very low levels of TRPM6 might be explained in the 
light of a transcriptional regulation, because both mRNA and protein are lower in drug resistant than in 
sensitive cells. Since TRPM6 is needed for Mg absorption by epithelial cells and contributes to systemic 
Mg homeostasis7, we hypothesize that resistant cells are less differentiated than sensitive cells, but more 
studies are needed to clarify this issue.
TRPM6 seems to function when assembled with TRPM733. Indeed, even though the stoichiometry 
remains to be elucidated, TRPM6 and 7 both participate to the heteromeric channel pore34 and recent 
data indicate that the heteromeric TRPM6/7 channel is more efficient in regulating divalent ion influx 
than homomeric channels constituted by TRPM6 or 7 alone35. Recently, in HEK-293 cells, TRPM6 has 
also been shown to adjust the cell distribution of TRPM7 through its kinase activity34. Since i) low 
amounts of TRPM7 decrease Mg influx in LoVo-R and ii) silencing TRPM7 in LoVo-S reduces Mg entry, 
our results suggest that TRPM7 is a crucial channel for Mg entry in LoVo cells.
More importantly, we provide evidence that TRPM7 is involved in modulating drug resistance in 
LoVo cells. Indeed, downregulating TRPM7, but not TRPM6, expression by siRNA enhances cell via-
bility of LoVo-S exposed to DXR. On the other hand, calpeptin, which upregulates TRPM7, renders 
LoVo-R more sensitive to the toxic effect of DXR. We therefore hypothesize that a link exists between low 
amounts of TRPM7, high intracellular magnesium and drug resistance. Since TRPM7 is also a kinase8–14, 
its inhibition might alter the phosphorylation of downstream targets, eventually contributing to the reg-
ulation of drug resistance.
We conclude that Mg homeostasis and the expression of two Mg channels, TRPM6 and 7, are altered 
in drug resistant colon carcinoma cells. In particular, TRPM6 may represent a key player in this model, 
as TRPM7 silencing appears to shift the phenotype of sensitive LoVo cells to one more similar to resistant 
cells. These findings reinforce previous reports underscoring the existence of a Mg-regulating mechanism 
in drug resistance4,36, and suggest that TRPM7 expression and/or activity may constitute novel targets for 
therapeutic intervention and circumvention of chemoresistance.
Methods
Cell culture. Colon cancer LoVo cells sensitive (LoVo-S) or resistant to DXR (LoVo-R) (kindly 
donated by Dr. P. Perego, Istituto Nazionale Tumori, Milano) were cultured in DMEM containing 10% 
fetal bovine serum and 2 mM glutamine at 37 °C and 5% CO2.
To obtain a transient downregulation of TRPM6 and 7, we utilized the stealth siRNAs developed by 
Qiagen37. siRNAs were transfected into 2 × 104/cm2 cells using HiPerFect Transfection Reagent (Qiagen). 
Non-silencing, scrambled sequences were used as controls (CTR).
To evaluate sensitivity to DXR, cell viability was assessed by MTT assay. Briefly, cells were seeded 
in 96 well/plates. Where indicated, 16 h prior to DXR treatment, LoVo-S were silenced for TRPM7 
or TRPM6, or exposed to 2-aminoethoxydiphenyl borate (2-APB, 50 μ M), while LoVo-R were treated 
with calpeptin (5 μ g/ml). After 48 h of DXR treatment (1 μ g/ml), culture medium was replaced with 
medium containing 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT, 0.5 mg/ml) 
(Sigma, Oakville, Ontario, Canada). At the end of the experiment, media were removed and formazan 
crystals generated by cellular reductase activity were dissolved in DMSO:ethanol (1:1) and quantified by 
absorbance readings at 575 nm. The experiment was repeated three times in quadruplicates. Percentage 
cell viability was calculated from the absorbance measured in DXR-treated vs. untreated cells for each 
experimental condition.
To assess DXR retention, cells were loaded with 10 μ M DXR for 2 h and fixed either immediately (load-
ing control) or 30 min after washing (efflux). Nuclear fluorescence was visualized by confocal microscopy 
and quantified as the mean nuclear fluorescence measured in efflux conditions vs. loading control.
Real-Time PCR. Total RNA was extracted by the PureLink RNA Mini kit (Ambion). Single-stranded 
cDNA was synthesized from 0.2 μ g RNA in a 40 μ l final volume using High Capacity cDNA Reverse 
Transcription Kit, with RNase inhibitor (Applied Biosystems) according to the manufacturer’s instruc-
tions. Real-time PCR was performed in triplicate on the 7500 FAST Real Time PCR System instrument 
using TaqMan Gene Expression Assays (Life Technologies, Monza, Italy): Hs00918928_g1 (TRPM7) and 
Hs01019353_m1 (TRPM6). The housekeeping gene GAPDH (Hs99999905_m1) was used as an internal 
reference gene. Relative changes in gene expression (defined as FC) were analyzed by the 2-ΔΔCt method38.
Western blot analysis. Cells were lysed in lysis buffer (50 mM TrisHCl pH 8.0, 150 mM NaCl, 1 mM 
EDTA, 1% NP-40). Protein concentration was determined using the Bradford protein assay (Bio-Rad). 
Cell extracts (100 μ g/lane) were resolved by 8% SDS-PAGE, transferred to nitrocellulose sheets at 100 mA 
for 16 h, and probed with anti-TRPM7 (Bethyl), anti-TRPM6 (Osenses), and anti-actin (Sigma Aldrich) 
antibodies. Secondary antibodies were labelled with horseradish peroxidase (GE Healthcare). The 
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SuperSignal chemiluminescence kit (Pierce) was used to detect immunoreactive proteins. All the results 
were reproduced at least three times and a representative Western blot is shown. Full length blots are 
shown in the Supplementary Information. Densitometric analysis was performed by the ImageJ software 
and TRPM7 or 6/actin ratio was calculated on three separate experiments (see supplementary).
Mg influx measurements. Subconfluent cells on 35-mm microscopy dishes (μ -dish, Ibidi) were 
loaded with 3 μ M Mag-Fluo-4-AM (Invitrogen), and imaged in a Na, Ca and Mg-free buffer at a 
confocal laser scanning microscope, as previously described39. Cytosolic fluorescence signals were 
recorded as time series of 5 min at a sampling frequency of 30 frames/min. The baseline was mon-
itored for 30 sec, then MgSO4 was added dropwise at a final concentration of 20 mM. Changes in 
intracellular Mg levels at single cell level were estimated by the mean fluorescent increment Δ F/F38. 
Image analysis was performed by Leica Confocal Software and 10 representative cells were examined 
in each microscopic field.
Quantification of total cell Mg. Total Mg content was assessed on sonicated cells by using the flu-
orescent chemosensor DCHQ540. Briefly, DCHQ5 was dissolved to a final concentration of 15 μ M in a 
mixture which contains 10% of Phosphate Buffer Saline (PBS) in a solution 1:1 of MeOH:MOPS 2 mM 
(pH 7.4). To perform standard curve, different amounts of MgSO4 were added and the fluorescence 
intensities were acquired at 510 nm. Mg concentrations of the samples were obtained by the interpolation 
of their fluorescence with the standard curve and were referred to the actual cell volume measured as 
described in the next paragraph.
Cell volume assessment. LoVo-S and LoVo-R were trypsinized and resuspended in PBS. Cells volume 
was calculated assessing the diameter cell profile by using a Beckman Coulter counter (Beckman Coulter). 
The cells volume is given in terms of equivalent spherical diameter. The analysis were carried out in triplicate.
Quantification of free Mg and Ca. Cells were trypsinized, washed and resuspended at 2 × 106/mL 
in loading buffer (LB) containing 120 mM NaCl, 20 mM HEPES, 4.7 mM KCl, 1.2 mM KH2PO4, 10 mM 
glucose, 1.2 mM CaCl2, and 1.2 mM MgSO4. Cells were loaded in LB containing 3 μ M Mag-Fura-2-AM 
or Fura-2-AM (for Mg2+ and Ca2+ measurements, respectively) for 30 min at 37 °C, then washed twice 
and maintained further 30 min in LB to allow for complete de-esterification of AM esters. Analysis was 
performed at a FluoroMax-4 spectrofluorometer (Horiba Jobin Yvon) at 37 °C. Fura dyes were excited 
with dual excitation wavelengths at 330 and 369 nm and emission was monitored at 511 nm. Ratio cali-
bration was performed by the in-built software HJY Multigroup, using Rmin and Rmax values obtained by 
sequential addition of 25 mM MgSO4, 0.05% Triton and 50 mM EDTA for Mag-Fura-2, or 10 mM CaCl2, 
0.05% Triton and 10 mM EGTA for Fura-2. Dissociation constants of 1.5 mM41 or 224 nM42 were used 
for Mag-Fura-2-AM or Fura-2-AM, respectively.
Statistical analysis. Statistical significance was determined using Student’s t test and set as following: 
*P < 0.05, **P < 0.01, ***P < 0.001.
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